Polygenic Risk Score Modifies Breast Cancer Risk in Pathogenic Variant Carriers

Jul 01, 2020

|

NEW YORK – A polygenic risk score for breast cancer can modify risk assessments for individuals who are carriers of pathogenic breast cancer variants, a new analysis has found.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Featured White Papers

Seeing Beyond the Limit: Detect Residual Disease and Assess Treatment Response

A Personalized, Tumor-Informed Approach to Detect Molecular Residual Disease With High Sensitivity and Specificity

BCR-ABL1 Minor Breakpoint (e1a2) Monitoring Using an Analytically Validated Multiplex Assay

Modifications to RNA Isolation Protocols Meet Requirements for Modern CML Monitoring of BCR-ABL1 Transcript Levels

Aug

24

Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug

25

Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Sep

10

Featured Webinar

Development of RNA-Based Predictive Response Signatures as Companion Diagnostics

This webinar, Part 2 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will focus on the development of RNA-based companion diagnostics for oncology.

Oct

08

Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Menu

Polygenic Risk Score Modifies Breast Cancer Risk in Pathogenic Variant Carriers

To read the full story....

Breaking News

GeneCentric Therapeutics, Janssen Partner to Uncover Bladder Cancer Biomarkers

KAHR Medical to Initiate Trial of Dual-Signaling Protein in Patients With Advanced Solid Tumors

Caris Life Sciences, Elevation Oncology Partner on Patient Enrollment for Tumor-Agnostic Drug Trial

Hemogenyx Partners With UPenn to Study CAR T-Cell Therapy in AML

T Cell Receptor Repertoire Linked to Anti-PD-1 Therapy Response in Hodgkin Lymphoma

Xcovery's Ensartinib Extends PFS in First-Line Advanced ALK-Positive NSCLC

Featured White Papers

Utility of Novel RNA-Based Tools in Oncology Drug Development

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Development of RNA-Based Predictive Response Signatures as Companion Diagnostics

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

What's Popular?

Research Advocates, Leading Docs to Expand Precision Medicine Access With Decentralized Model

Guardant Health CDx Wins FDA Approval for First Liquid Biopsy NGS Tumor Profiling Assay

Hemogenyx Partners With UPenn to Study CAR T-Cell Therapy in AML

Real-World Data Reinforces Survival Benefit of Sequential Gilotrif, Tagrisso in EGFR-Mutated NSCLC

Caris Life Sciences, Elevation Oncology Partner on Patient Enrollment for Tumor-Agnostic Drug Trial

Sponsorships